SNDX
USDSyndax Pharmaceuticals Inc. Common Stock
Echtzeitkurs
Kursdiagramm
Schlüsselkennzahlen
Marktkennzahlen
Eröffnung
$13.600
Hoch
$15.799
Tief
$13.150
Volumen
3.36M
Unternehmensfundamentaldaten
Marktkapitalisierung
1.3B
Branche
Biotechnologie
Land
United States
Handelsstatistiken
Durchschnittliches Volumen
2.67M
Börse
NMS
Währung
USD
52-Wochen-Spanne
Ähnliche Nachrichten
UBS Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $38
UBS analyst David Dai maintains Syndax Pharmaceuticals with a Buy and raises the price target from $35 to $38.
Barclays Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $22
Barclays analyst Peter Lawson maintains Syndax Pharmaceuticals with a Overweight and raises the price target from $19 to $22.
Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
– 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax's leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an
Syndax Announces Participation in November Investor Conferences
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief
Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals with a Buy and maintains $40 price target.
Ähnliche Aktien
ELMD
Electromed Inc.
WHLR
Wheeler Real Estate Investment Trust Inc.
RMNI
Rimini Street Inc. (DE)
RZB
Reinsurance Group of America Incorporated 5.75% Fixed-To-Floating Rate Subordinated Debentures due 2056
CXT
Crane NXT Co.
Bleiben Sie auf dem Laufenden
Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.